(Q28277470)

https://api.crossref.org/works/10.1517/14712598.7.1.123

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/14712598.7.1.123

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/14712598.7.1.123

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/14712598.7.1.123

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/14712598.7.1.123

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.123

Integrins: bidirectional, allosteric signaling machines

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.123

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.123

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.123

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.123

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.123

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.123

Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.123

Overlapping roles of P-selectin and alpha 4 integrin to recruit leukocytes to the central nervous system in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.123

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.123

Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.123

A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.123

Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.123

The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.123

A controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.123

An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.123

Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.123

Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.123

Midlife cardiovascular risk factors and risk of dementia in late life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.123

Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.123

Mechanisms of disability progression in primary progressive multiple sclerosis: are they different from secondary progressive multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.123

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.123

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.123

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.123

α4Integrins as Therapeutic Targets in Autoimmune Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.123